A 2026 BD opportunity scan of Chengdu Kanghong Pharmaceutical Group Co., Ltd, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of ASKA Pharmaceutical Co, Ltd, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Asahi Kasei Therapeutics Corporation., covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Chengdu Brilliant Pharmaceutical CO., LTD., covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Ferring Pharmaceuticals, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Betta Pharmaceuticals Co., Ltd, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Azurity Pharmaceuticals, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Changchun Genescience Pharmaceutical, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

NCT07435012 clinical trial report covering TH-07, Phase 3, endpoints, sponsor, geography, readout timing and development white space.

NCT07434973 clinical trial report covering Cannabidiol, Phase 3, endpoints, sponsor, geography, readout timing and development white space.

CTR20260731 clinical trial report covering Urea-13C, Phase 3, endpoints, sponsor, geography, readout timing and development white space.

NCT07435051 clinical trial report covering Vancomycin Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.